Anixa Biosciences, Inc. (NASDAQ:ANIX – Get Free Report) Director Arnold M. Baskies purchased 5,000 shares of the company’s stock in a transaction dated Tuesday, January 28th. The stock was purchased at an average price of $2.82 per share, with a total value of $14,100.00. Following the transaction, the director now owns 120,000 shares of the company’s stock, valued at approximately $338,400. This represents a 4.35 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Anixa Biosciences Trading Down 2.0 %
NASDAQ:ANIX opened at $2.94 on Friday. The firm has a market cap of $94.66 million, a price-to-earnings ratio of -7.54 and a beta of 0.90. Anixa Biosciences, Inc. has a 12-month low of $2.07 and a 12-month high of $4.70. The company’s 50-day moving average is $2.74 and its two-hundred day moving average is $3.05.
Anixa Biosciences (NASDAQ:ANIX – Get Free Report) last announced its earnings results on Friday, January 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02. On average, equities research analysts forecast that Anixa Biosciences, Inc. will post -0.46 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Anixa Biosciences
Analyst Ratings Changes
A number of equities analysts have issued reports on ANIX shares. D. Boral Capital restated a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research report on Wednesday, January 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Anixa Biosciences in a research note on Tuesday, November 19th.
Get Our Latest Report on Anixa Biosciences
Anixa Biosciences Company Profile
Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.
Featured Stories
- Five stocks we like better than Anixa Biosciences
- How to Most Effectively Use the MarketBeat Earnings Screener
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Are Penny Stocks a Good Fit for Your Portfolio?
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Comparing and Trading High PE Ratio Stocks
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.